A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
DRUG: OPB-111077|DRUG: OPB-111077
Dose-limiting toxicity (DLT), The tolerability of OPB-111077 in combination with bendamustine and rituximab, 23days|Incidence of Adverse events(AEs), Safety of OPB-111077 in combination with bendamustine and rituximab, Up to 3 years
Efficacy based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014)), * Percentage of Participants with Complete Response based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014))
* Percentage of Participants with Complete Response and Partial Response based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014)), Last dose of study drug (up to 3 years)
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.